Journal of Health Sciences and Medicine

Yazarlar: ["Tuba ALTUĞ", "Ayşegül ŞENTÜRK", "Murat ALIŞIK", "Cemile BİÇER"]

Konular:-

DOI:10.32322/jhsm.1093848

Anahtar Kelimeler:Pulmonary thromboembolism,H-FABP,Cardiac enzymes,Prognostic factors,Thrombolytic treatment

Özet: Introduction: To investigate factors which could possibly be prognostic, to decide on thrombolytic therapy as soon as possible, and to determine the prognostic value of H-FABP, which is a new marker, in pulmonary thromboembolism. Material and Method: In our study, a patient group, consisting of 58 patients diagnosed with PTE and a control group of 30 healthy individuals were investigated. According to their risk of mortality, patients were analyzed in three groups: high, moderate and low. The moderate mortality risk groups were categorized into two groups according to PAP and patients with PAP≥45 mmHg were “Group 1” and PAP<45 mmHg were “Group 2”. Differences in levels of H-FABP and other cardiac prognostic markers between these groups were analyzed. Results: H-FABP level was measured as 507.6±99.3 pg/ml in the control group and 3203.1±2389.3 pg/ml in the patient group. H-FABP level was found to be the highest in the high mortality risk group, and the lowest in the low mortality risk group (p<0.001). Moreover, in the subgroups of moderate mortality risk group, H-FABP levels were significantly higher in group 1 compared to group 2. For the evaluation of other cardiac markers in PTE subgroups, pro-BNP level was the highest in the high mortality risk group, and the lowest in the low mortality risk group. Conclusion: The findings in this study show that, H-FABP is a superior marker in determining the prognosis compared to pro-BNP and troponin. High PAP level is one of the important prognostic markers that should be considered along with the electrocardiography findings.

---